NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company collaborating with the Children’s Hospital Los Angeles (CHLA). NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational support team.
NanoValent's core technology is the NanoMod™ - a new generation, nanoparticle based ADC (antibody-drug conjugated) technology able to reposition and enhance cancer therapies.
OUR MISSION
NVP is advancing a new generation and uniquely targeted nanoparticle based ADC (antibody-drug conjugated) technology (NanoMod™) that may provide much greater flexibility and choice for patients restricted by both current and even emerging treatment options.
NVP is advancing a new generation and uniquely targeted nanoparticle based ADC (antibody-drug conjugated) technology (NanoMod™) that may provide much greater flexibility and choice for patients restricted by both current and even emerging treatment options.
For more information contact Mark Lewis, mlewis@nanovalent.com